Alkermes开始验证ALKS 4230治疗晚期实体瘤的有效性

2019-02-28 不详 网络

Alkermes公司近日宣布启动ARTISTRY-2试验,这是一项新的针对候选药物ALKS 4230的临床研究。ARTISTRY-2试验将评估ALKS 4230单药皮下注射及与PD-1抑制剂KEYTRUDA®(pembrolizumab)联合使用治疗晚期实体瘤患者的有效性和安全性。

Alkermes公司近日宣布启动ARTISTRY-2试验,这是一项新的针对候选药物ALKS 4230临床研究。ARTISTRY-2试验将评估ALKS 4230单药皮下注射及与PD-1抑制剂KEYTRUDA®pembrolizumab)联合使用治疗晚期实体瘤患者的有效性和安全性。ALKS 4230是一种新型的工程化融合蛋白,设计用于选择性地激活具有肿瘤杀伤作用的免疫细胞,同时能够结合中间亲和性白细胞介素-2IL-2)受体复合物来避免免疫抑制细胞的扩增。

ARTISTRY-2是一项I/II期研究,该研究将首先进行ALKS 4230的剂量递增分析。剂量递增阶段旨在评估递增剂量的ALKS 4230的安全性和耐受性。在确定最佳剂量和给药方案后,将评估晚期实体瘤患者对ALKS 4230的总体响应率、响应持续时间、特定时间点的非进展率和总体存活率。


原始出处:

http://www.firstwordpharma.com/node/1626837#axzz5gj4KGYJT

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636429, encodeId=df62163642986, content=<a href='/topic/show?id=9f1523180a' target=_blank style='color:#2F92EE;'>#ALKS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2318, encryptionId=9f1523180a, topicName=ALKS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b1122641324, createdName=1179102698_36768933, createdTime=Mon Apr 15 20:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443139, encodeId=a82e144313903, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Sat Mar 02 08:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590805, encodeId=41ed1590805ac, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Sat Mar 02 08:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636429, encodeId=df62163642986, content=<a href='/topic/show?id=9f1523180a' target=_blank style='color:#2F92EE;'>#ALKS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2318, encryptionId=9f1523180a, topicName=ALKS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b1122641324, createdName=1179102698_36768933, createdTime=Mon Apr 15 20:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443139, encodeId=a82e144313903, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Sat Mar 02 08:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590805, encodeId=41ed1590805ac, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Sat Mar 02 08:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636429, encodeId=df62163642986, content=<a href='/topic/show?id=9f1523180a' target=_blank style='color:#2F92EE;'>#ALKS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2318, encryptionId=9f1523180a, topicName=ALKS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b1122641324, createdName=1179102698_36768933, createdTime=Mon Apr 15 20:52:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443139, encodeId=a82e144313903, content=<a href='/topic/show?id=feee598219f' target=_blank style='color:#2F92EE;'>#晚期实体瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59821, encryptionId=feee598219f, topicName=晚期实体瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55065029738, createdName=446798725_87912766, createdTime=Sat Mar 02 08:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590805, encodeId=41ed1590805ac, content=<a href='/topic/show?id=0c0b115e4cf' target=_blank style='color:#2F92EE;'>#MES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11574, encryptionId=0c0b115e4cf, topicName=MES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=874617863969, createdName=longqijun254, createdTime=Sat Mar 02 08:52:00 CST 2019, time=2019-03-02, status=1, ipAttribution=)]
    2019-03-02 longqijun254

相关资讯

FDA向Alkermes的实验性抗抑郁药ALKS 5461发出拒绝提交函

近日,Alkermes表示,FDA对其实验性药物ALKS 5461持否定态度,该药是一种每日给药一次治疗重度抑郁症以及对标准抗抑郁药反应不足的患者的口服疗法。根据Alkermes的说法,FDA这项决定的理由为“对所提出适应症的总体有效性证据不足”,并且在重新提交之前,Alkermes需要进一步开展ALKS 5461的临床试验。